Bio-Techne Corporation logo
TECHBio-Techne Corporation

Quick Ratio (Acid-Test): 3.18

popular:market cap|pe ratio|revenue|price history|total return

Is the quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 3.18 is in line with its 5-year average of 2.94, near the high end of its 5-year range (2.38–3.50).

As of Saturday, June 27, 2026. 13.26% above its 12-month average of 2.80.

Current Ratio|Debt to Equity|P/FCF Ratio|All Metrics
Quick Ratio

TECH Quick Ratio

3.18

Reported quarterly quick ratio; no daily interpolation.

+22.82% 5Y
TECH Quick Ratio (Acid-Test)

TECH Average Quick Ratio (Acid-Test) Chart

TECH Quick Ratio (Acid-Test)

TECH Current vs Average Quick Ratio (Acid-Test) Chart

TECH Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

3.18

QUICK RATIO (ACID-TEST) AVG TTM

2.80

QUICK RATIO (ACID-TEST) AVG 3Y

2.94

QUICK RATIO (ACID-TEST) AVG 5Y

2.94

QUICK RATIO (ACID-TEST) AVG 10Y

3.09

QUICK RATIO (ACID-TEST) AVG 15Y

3.64

QUICK RATIO (ACID-TEST) AVG 20Y

7.17

CURRENT VS TTM AVG

+13.26%

CURRENT VS 3Y AVG

+8.03%

CURRENT VS 5Y AVG

+7.87%

CURRENT VS 10Y AVG

+2.93%

CURRENT VS 15Y AVG

-12.63%

CURRENT VS 20Y AVG

-55.72%

TECH Competitors' Quick Ratio (Acid-Test)

NAMEMARKET CAPQUICK RATIO (ACID-TEST)TTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B3.182.802.942.94
Insulet Corp. (PODD)vs ›$10.86B2.112.422.513.28
Baxter International Inc. (BAX)vs ›$11.38B1.561.311.231.40
Molina Healthcare, Inc. (MOH)vs ›$11.79B1.691.661.581.56
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.370.330.350.35
Charles River Laboratories International, Inc. (CRL)vs ›$10.20B1.021.071.101.11
Tempus AI, Inc. (TEM)vs ›$9.80B3.002.582.233.05
Henry Schein, Inc. (HSIC)vs ›$9.68B0.760.770.860.88
Revvity, Inc. (RVTY)vs ›$12.61B1.402.212.021.79
Align Technology, Inc. (ALGN)vs ›$12.78B1.241.171.111.16

Liquidity Comparison

Quick Ratio

3.18

Excludes inventory

Current Ratio

3.46

Includes inventory

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio = (Current Assets − Inventory) / Current Liabilities

The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The quick ratio (acid-test) for TECH stock is 3.18.
Is Bio-Techne Corporation's quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.18 is in line with its 5-year average of 2.94, near the high end of its 5-year range (2.38–3.50).
What is the TTM average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The TTM average quick ratio (acid-test) for TECH stock is 2.80.
What is the 3Y average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The 3Y average quick ratio (acid-test) for TECH stock is 2.94.
What is the 5Y average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The 5Y average quick ratio (acid-test) for TECH stock is 2.94.
What is the 10Y average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The 10Y average quick ratio (acid-test) for TECH stock is 3.09.
What is the 15Y average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The 15Y average quick ratio (acid-test) for TECH stock is 3.64.
What is the 20Y average quick ratio (acid-test) for Bio-Techne Corporation (TECH)?
The 20Y average quick ratio (acid-test) for TECH stock is 7.17.

TECH Quick Ratio (Acid-Test) History

DATEQUICK RATIO (ACID-TEST)
2026-03-313.18
2025-12-313.08
2025-09-302.81
2025-06-302.38
2025-03-312.58
2024-12-312.77
2024-09-303.26
2024-06-302.75
2024-03-312.88
2023-12-313.03
2023-09-303.17
2023-06-303.50
2023-03-312.84
2022-12-313.15
2022-09-302.92
2022-06-302.64
2022-03-312.79
2021-12-313.03
2021-09-303.18
2021-06-302.59
2021-03-313.32
2020-12-313.70
2020-09-304.13
2020-06-303.92
2020-03-313.74
2019-12-313.52
2019-09-303.41
2019-06-303.15
2019-03-313.36
2018-12-313.31
2018-09-303.50
2018-06-303.97
2018-03-314.29
2017-12-312.49
2017-09-302.25
2017-06-302.11
2017-03-311.70
2016-12-311.89
2016-09-302.24
2016-06-303.63
2016-03-314.37
2015-12-315.57
2015-09-304.04
2015-06-305.00
2015-03-316.33
2014-12-314.98
2014-09-305.32
2014-06-3016.31
2014-03-3111.54
2013-12-3110.82
2013-09-3011.87
2013-06-3011.68
2013-03-3110.91
2012-12-3115.15
2012-09-3013.61
2012-06-308.62
2012-03-318.65
2011-12-3113.19
2011-09-306.74
2011-06-3010.20
2011-03-3115.91
2010-12-3117.54
2010-09-3013.66
2010-06-3011.00
2010-03-3110.42
2009-12-3121.04
2009-09-3016.80
2009-06-3015.73
2009-03-3114.21
2008-12-3114.06
2008-09-3012.45
2008-06-3012.30
2008-03-3112.37
2007-12-3111.51
2007-09-3015.00
2007-06-3011.87
2007-03-3111.64
2006-12-3112.99
2006-09-305.58
2006-06-307.84
2006-03-3110.07
2005-12-318.77
2005-09-309.78
2005-06-309.08
2005-03-315.64
2004-12-3110.78
2004-09-308.56
2004-06-3015.12
2004-03-3113.43
2003-12-3113.90
2003-09-3014.87
2003-06-3013.25
2003-03-319.68
2002-12-3110.89
2002-09-306.59
2002-06-308.41

Related Metrics

Current RatioDebt to EquityP/FCF RatioAll Metrics

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
www.bio-techne.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman
View full financials